GSK And Novartis Look To Emerging Markets Even As Growth Slowed In Q1 – Emerging Market Earnings Roundup (Part 3)
This article was originally published in PharmAsia News
Executive Summary
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.
You may also be interested in...
GSK And HGS Face Off Over Buyout
Human Genome Sciences says the long-term blockbuster opportunity in Benlysta and the potential of its pipeline products are under-valued by GlaxoSmithKline’s takeover offer. Management at GSK, however, plays down any talk of increasing its bid.
Novartis Revises U.S. Regulatory Strategy For Key Respiratory Drug
The Swiss drug maker says it has agreed with FDA on a Phase III trial design for the combination respiratory drug QVA149 and expects to file in late 2014; plan now calls for testing a twice-daily dose in addition to once-daily.
Only Alli Remains After Glaxo’s OTC Transaction With Aspen
GlaxoSmithKline sells 19 OTC brands – worth about 1% of its consumer healthcare business – outside the U.S., Canada and Europe to South African firm Aspen Pharmacare. Weight-loss drug alli is GSK’s final remaining non-core OTC following the $263 million deal.